Technology | 2019.10.24
ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease
New resources detail positive impact of aducanumab pivotal trial results and recent progress of ProMIS pipeline programs TORONTO and CAMBRIDGE, MA, Oct. 24, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]heimers-disease-300944480.html
Follow us on
Instagram is adding automatic in-app text translation - The Verge views: 1568
Instagram is adding automatic in-app text translation - The Verge views: 1507